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Background: Pseudomonas aeruginosa airway infections are a major cause of morbid-
ity and mortality in patients with cystic fibrosis (CF). Azithromycin improves the related 
clinical outcomes, but its mechanisms of action remain poorly understood. We tested 
the hypothesis that azithromycin downregulates P. aeruginosa-induced pro-inflammatory 
responses by modifying release of bacterial proteins.
Methods: We monitored inflammatory markers in lungs of CF mutant mice and their 
littermate controls in response to conditioned media (CM) collected from the reference 
P. aeruginosa PAO1 strain cultured in the presence or in the absence of azithromycin. 
A mass spectrometry-based proteomic approach was applied to examine whether the 
macrolide elicits a differential release of bacterial proteins.
results: CM collected from azithromycin-untreated PAO1 cultures induced powerful 
pro-inflammatory neutrophil-dominated responses. Azithromycin attenuated the 
responses, mainly of macrophage chemoattractant protein-1, tumor necrosis factor-α, 
and interferon-γ, in CF but not in wild-type mice. Proteomic analysis showed that 
azithromycin upregulated an array of bacterial proteins including those associated 
with regulation of immune functions and with repair and resolution of inflammatory 
responses like the chaperone DnaK and the S-adenosylmethionine synthase, while it 
downregulated the extracellular heme acquisition protein HasA and the catalytic enzyme 
lysylendopeptidase.
conclusion: Supernatants collected from cultures of the bacterial strain PAO1 represent 
a novel experimental model to trigger in vivo lung inflammatory responses that should 
Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; MudPIT, multidimensional 
protein identification technology.
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inTrODUcTiOn
Recurrent endobronchial infections by the opportunistic 
Gram-negative bacterium Pseudomonas aeruginosa are associ-
ated with high morbidity and mortality in cystic fibrosis (CF). 
The virulence of P. aeruginosa stems from multiple factors such 
as its ability to release bacterial toxins, to develop antibiotic 
resistance, to form biofilm, to employ a range of cell-to-cell 
communication signals through quorum-sensing systems, and 
to acquire a mucoid phenotype; all these attributes render the 
microbe resistant to the innate and acquired immunologic 
defenses of the host (1, 2). Colonization of CF lungs with 
P.  aeruginosa increases rates of lung function decline, worsens 
the prognosis of the disease, and is a significant predictor of mor-
tality (3, 4). Active treatment of lung disease is a cornerstone of 
CF management. This may include anti-inflammatory therapy 
approaches in combination with antibiotic therapies (5–7) to 
circumvent the unbalanced exaggerated pro-inflammatory 
and decreased anti-inflammatory reactions. These have been 
considered in CF either as intrinsic or as a response to present 
or recent infection (8–11). Treatment with azithromycin, a 
macrolide antibiotic structurally modified from erythromycin, 
has been reported to attenuate symptoms in CF patients, result-
ing in significant clinical improvement in lung function with 
reduction in pulmonary exacerbations and fewer courses of 
antibiotic use (12–16). Regulation of bacterial virulence factors 
(17) and anti-inflammatory effects (18) of the macrolide have 
been postulated, but its underlying mechanisms of action are 
still under debate.
We hypothesized that azithromycin modulates P. aeruginosa-
induced lung inflammation in CF by modifying release of 
bacterial products. After validating the model of conditioned 
media (CM) collected from the reference P. aeruginosa PAO1 
strain to induce lung inflammation, we examined the influence 
of pre-treating bacterial cultures with azithromycin on lung 
pro-inflammatory markers in CF mice homozygous for the 
F508del mutation (F508del-CF) and in wild-type mice. CMs 
collected from PAO1 were analyzed by a mass spectrometry 
(MS)-based proteomic approach to characterize the differen-
tially released bacterial proteins and to identify possible targets 
of the macrolide.
MaTerials anD MeThODs
animal Model
Female CF mice homozygous for the F508del-CFTR mutation 
built in the 129/FVB outbred background (Cftrtm1Eur) (19), 
and their normal homozygous wild-type littermates were 
studied. Mouse age ranged from 10 to 16  weeks and their 
weights between 20 and 30 g. Animals were housed following 
European recommendations (20) and regulations (CEE no. 
86/609). The experimental protocol was approved by the local 
Ethics Committee for animal research (2013/UCL/MD/012). To 
prevent intestinal obstruction in CF mice, Movicol (55.24 g/L) 
was administered in demineralized acidified drinking water. 
The genotype of each animal was checked at 21 days of age, as 
described previously (18).
collection of Bacterial cM
The reference (ATCC 15692) P. aeruginosa PAO1 was chosen 
as it represents the most commonly used strain in research 
on this ubiquitous opportunistic Gram-negative microorgan-
ism. Collection of bacterial CM was obtained, as described 
previously (21). Briefly, the strain was seeded onto Difco™ 
Tryptic Soy Agar (TSA; Becton Dickinson and Co., Le Point 
de Claix, France) plates and allowed to grow overnight at 37°C. 
After seeding onto modified Vogel–Bonner medium (MVBM), 
cultures were incubated overnight under continuous agitation. 
The next day, P. aeruginosa bacteria were diluted in MVBM 
to reach 10−8 CFU/mL (optical density, OD of 0.1 at 600 nm) 
and incubated at 37°C for 16 h in the absence or in the pres-
ence of 8  mg/L azithromycin. This concentration is in the 
subminimum inhibitory range for P. aeruginosa and consistent 
with the concentration found in lung of patients treated with 
multiple azithromycin doses of 500 and 1000  mg daily (22). 
P. aeruginosa cultures, normalized to 0.2 OD at 600 nm, were 
collected by centrifugation (7000 ×  g, 30  min, 4°C) followed 
by filtration (0.22 μm filter) to remove any remaining bacteria. 
CMs were concentrated 17-fold using Amicon® Ultra-15 30K 
NMWL centrifugal filter devices (Millipore Corporation, 
Bedford, MA, USA) precoated with 10  mg/mL bovine serum 
albumin (BSA, Sigma Chemical, St. Louis, MO, USA). CM 
samples were ultra-centrifuged (70,000 × g, 1 h, 4°C), filtered 
on gel (PD-10 Desalting columns; GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden), and finally filtered on 0.22  μm filter 
and stored at −80°C.
induction of lung inflammation by 
exposure to lPs or cM
Weight-matched F508del-CF and normal homozygous wild-type 
mice were anesthetized with an intraperitoneal (i.p.) injection of 
a mixture of 100 mg/kg ketamine (Parke-Davis, Ann Arbor, MI, 
USA) and 15  mg/kg xylazine (Bayer, Leverkusen, Germany). 
As a reference model of induction of acute lung inflammation, 
a standard dose of LPS (Sigma Chemical, St Louis, MO, USA; 
50 μg/25  g body weight in 50 μL saline) was instilled into the 
be closer to those obtained with live bacteria, but without bacterial infection. Combined 
with a bactericidal effect, complex regulation of bacterial innate immune and metabolic 
factors released in the cultured medium by the action of the macrolide can contribute to 
its anti-inflammatory effects.
Keywords: azithromycin, cystic fibrosis, cytokines, inflammation, proteomics, Pseudomonas aeruginosa
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trachea through the mouth, using a laryngoscope and a fine pipette 
tip. To track, at a single-time point after LPS exposure, both the 
early cytokine responses and the late cell infiltrate responses, a 
validated combined protocol (23) using two consecutive doses 
(50 and 100 μg/25 g body weight in 50 μL saline) with a 21-h 
interval between doses was applied, with sampling taking place 
3 h after the last dose. In control experiments, sterile saline was 
used as solution for endotracheal instillation.
A volume of 50 μL CM collected from PAO1 was instilled 
into the mouse trachea. In order to select the optimal doses of 
CM, serial dilutions were tested at selected time points after 
endotracheal instillation. As for the LPS combined protocol, two 
CM doses were applied at an interval of 21 h with sampling 3 h 
after the last instillation.
Bronchoalveolar lavage
At selected time points after the last endotracheal instillation 
of NaCl, LPS, or CM, the mice were killed by i.p. injection 
of 20  mg sodium pentobarbital (Abbott, Chicago, IL, USA). 
Bronchoalveolar lavage (BAL) was then performed by can-
nulating the trachea and lavaging with 1.5  mL sterile saline, 
as described previously (18). The BAL fluid was centrifuged 
(250 × g, 10 min, 4°C) and the supernatant was aliquoted and 
stored at −80°C for further biochemical measurements unless 
otherwise stated. Cell pellets were resuspended in saline to 
count total cells in fresh preparations using a Burker cell. Cells 
were spread on microscope slides by cytospin centrifugation 
(Cytospin 3, Shandon, Pittsburgh, PA, USA). Differential 
cell counts (at least 200) were performed after fixation with 
methanol and staining using the Diff Quick method (Dade, 
Brussels, Belgium).
Biochemical analyses
The activity of the cytoplasmic enzyme lactate dehydrogenase 
(LDH) in fresh BAL fluid was evaluated spectrophotometrically 
based on the catalytic oxidation of l-lactate to pyruvate with 
concomitant reduction of nicotinamide adenine dinucleotide 
(NAD). The enzyme activity was measured by monitoring NADH 
formation at 340  nm. Linearity of the test ranges from 20 to 
3800 U/L.
Total protein content in fresh BAL fluid was analyzed by a 
dye-binding colorimetric assay using an automated pyrogallol 
red-molybdate-protein complex method (SYNCHRON LX®, 
Beckman Coulter, Brea, CA, USA). Color change (from red to 
blue under test conditions when complexed with proteins) was 
measured as absorbance change at 600 nm. The limit of detection 
was from 0.06 to 3.00 g/L.
The master cytokines [tumor necrosis factor (TNF)-α, inter-
leukin (IL)-1β, and IL-6]; the chemokines [keratinocyte chem-
oattractant (KC), macrophage chemoattractant protein (MCP)-1, 
and mouse macrophage inflammatory protein (MIP)-2]; IL-17 
and the Th-1-related cytokine, interferon (IFN)-γ, were simul-
taneously monitored in BAL fluid following the manufacturers’ 
protocol using a Multiplex assay (Merck Millipore, Darmstadt, 
Germany). The lower limit of detection for all cyto/chemokines 
was 3.2  pg/mL. In experiments conducted to validate the CM 
protocol, the two master cytokines TNF-α (BD Pharmigen; San 
Diego, CA, USA) and IL-1β (R&D Systems; Minneapolis, MN, 
USA) were monitored in BAL fluid using a standard sandwich 
enzyme-linked immunosorbent assay (ELISA). Their lower limit 
of detection was 15.6 pg/mL.
All biochemical analyses were performed in duplicates.
Quantification of lPs
The amounts of LPS in samples used for endotracheal instillation 
were measured using a chromogenic signal generated in the pres-
ence of the endotoxin by a limulus amebocyte lysate (LAL) Pierce 
chromogenic quantitation kit assay (ThermoFisher Scientific, 
Rockford, IL, USA). The reaction was measured on a microplate 
absorbance reader at 405 nm following the manufacturer’s pro-
tocol. A standard curve was created using LPS from P aeruginosa 
(1 mg/mL in NaCl). The microplate was incubated at 37°C for 
10 min, and the chromogenic substrate solution was then added. 
The reaction was stopped by adding 25% acetic acid within 6 min 
when a yellow color appeared. Values are expressed as endotoxin 
units (EU) with 1 EU/mL corresponding to 1 ng endotoxin/mL 
of solution. The limit of detection is 0.5 EU/mL. Quantification 
of LPS was performed in triplicates.
Proteomic analysis
Tryptic Digestion
Equal amounts of non-diluted CM (1 mL), collected from PAO1 
cultures in the presence or in the absence of azithromycin, were 
concentrated to 100 μL. The total protein content was quantified 
by SPN™-Protein Assay (G-Biosciences, St Louis, MO, USA). 
The 50 μg protein per sample was treated with RapiGest™ SF 
at 0.2% (w/v) (Waters Corporation, Milford, MA, USA). After 
incubation at 100°C for 5  min, samples were cooled to room 
temperature and digested with trypsin (Sequencing Grade 
Modified Trypsin, Promega, Madison, WI, USA) at an enzyme/
substrate ratio of about 1:50 (w/w). Samples were then incubated 
at 37°C overnight and another aliquot of trypsin [1:100 (w/w)] 
was added to samples further incubated at 37°C for 4  h. The 
enzymatic reaction was stopped by acidification with 0.5% 
trifluoroacetic acid (Sigma-Aldrich) followed by incubation at 
37°C for 45  min and centrifugation at 13,000 ×  g for 10  min. 
Samples were desalted by PepClean C-18 spin columns (Pierce 
Biothecnology Inc., Rockford, IL, USA), concentrated in a 
SpeedVac (Savant Instruments Farmingdale, NY, USA) at 60°C, 
and finally resuspended in 0.1% formic acid (Sigma-Aldrich Inc., 
St. Louis, MO, USA).
Mass Spectrometry-Based Proteomic Analysis
Trypsin-digested samples (n = 3 replicates per condition) were 
analyzed by multidimensional protein identification technology 
(MudPIT) based on two dimensional micro-liquid chromatog-
raphy coupled with tandem MS. Briefly, 3 μL of the digested 
peptide mixture were loaded by means of an autosampler 
(Suveyor AS Thermo) onto a strong cation exchange column 
(PolySULFOETHYL A™ Capillary, 0.3 mm i.d. × 100 mm, and 
5 μm, PolyLC Inc., Columbia, MD, USA) and then eluted using 
eight steps of increasing ammonium chloride concentrations 
(0, 20, 40, 80, 120, 200, 400, and 700  mM). Eluted peptides, 
obtained by each salt step, were first captured in turn onto 
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two peptide traps (Zorbax 300 SB C-18, 5  μm, and 0.3  mm 
i.d.  ×  5  mm, Agilent technologies, Santa Clara, CA, USA) 
mounted on a 10-port valve, for concentration and desalting, 
and subsequently loaded on a reversed phase C-18 column 
(BioBasic-18, 0.180  mm i.d.  ×  100  mm, and 5  μm, Thermo 
Electron Corporation, Bellofonte, PA, USA) for separation with 
an acetonitrile gradient. The flow rate on C-18 column was 
1 μL/min. Peptides eluted from the C-18 column were directly 
analyzed with a linear ion trap LTQ mass spectrometer (Thermo 
Fisher) equipped with a nanospray ion source. The spray capil-
lary voltage was set at 1.5  kV, while the ion transfer capillary 
temperature was held at 185°C. Full mass spectra were acquired 
in positive mode and over a 400–2000 m/z range, followed by 
five MS/MS events sequentially generated in a data-dependent 
manner on the five most-intense ions selected from the full MS 
spectrum, using dynamic exclusion for MS/MS analysis (colli-
sion energy 35%).
Proteomics Data Processing
The experimental MS/MS spectra produced by MudPIT were 
matched against the in  silico tryptic peptide sequences of the 
P. aeruginosa protein database (5679 protein sequences) retrieved 
from UNIPROT database1 on May 2015. Data processing was 
performed by Discoverer 2.0 software, based on SEQUEST HT 
algorithm (24). Peptide and protein assignment was made accord-
ing to specific guidelines (25). The following criteria were used for 
peptide identification: parent and fragment mass tolerance of 1 
and 0.6 Da, respectively, and missed cleavage sites per peptide of 
2. Matches between spectra were only retained if they had a mini-
mum Xcorr of 2.0 for +1, 2.5 for +2, and 3.5 for +3 charge state, 
respectively, protein rank was fixed to 1, while peptide confidence 
was set to “high.” In addition, the false discovery rate (FDR) was 
set to ≤3%. Based on a direct correlation between the spectral 
count (SpC) and the relative protein abundance, identified pro-
teins were semi-quantitatively compared by label-free approaches 
(26). Specifically, protein lists were processed by means of linear 
discriminant analysis (LDA) (27) using a common covariance 
matrix for all groups and the Mahalanobis distance (28) from 
each point to each group’s multivariate mean. To select proteins 
discriminating the analyzed P. aeruginosa conditions, we consid-
ered those with smallest p-value (≤0.05), while F ratio resulted 
≥9. The average SpC (aSpC) values of proteins selected by LDA 
were pairwise compared by Dave and DCI indices of MAProMa. 
In between-group comparisons, each protein resulted with a Dave 
value >|0.3|. Finally, proteins selected by LDA, Dave, and DCI 
indices were evaluated by unsupervised learning methods, such 
as hierarchical clustering (HC) (29), using in-house R-scripts, 
based on XlsReadWrite, clue, and clValid library2; Ward’s method 
and Euclidean distance metric were applied.
statistics
Statistical analysis was performed using JMP12 software (SAS 
Institute, Cary, NC, USA). Data are expressed as mean ±  SD, 
1 www.uniprot.org/.
2 http://cran.r-project.org.
where n refers to the number of animals per group. Between-group 
comparisons were evaluated assuming normal distributions by 
ANOVA with post hoc comparisons made by using Student’s t-test 
or Tukey–Kramer honestly significant difference test for two or 
more than two x-levels, respectively. Null hypothesis was rejected 
at p < 0.05.
resUlTs
Endotracheal instillation of CM collected from P. aeruginosa 
PAO1 strain was well tolerated by wild-type and F508del-CF 
mice, and no mortality was observed. As NaCl instillation does 
not influence any monitored inflammatory marker (18, 23), 
values obtained under saline-treated conditions in wild-type or 
in F508del-CF mice were considered as control reference values 
for the corresponding genotype group.
cM from Pseudomonas induces strong 
Pro-inflammatory responses
To validate the CM collected from PAO1 cultures as a model to 
study in vivo inflammatory responses, a first series of experiments 
was conducted to select its optimal dilution either at 3  h after 
mouse instillation, to evaluate early cytokine release responses, or 
at 24 h after mouse instillation, to evaluate late cellular infiltrate 
responses (18). We then measured release of the representative 
TNF-α master cytokine and cell counts, 3 and 24 h, respectively, 
after instillation of CM diluted (0, 3, 10, and 30 times) with saline. 
As a control, the effects were compared with those analyzed at 
the same time point after a single standard dose of LPS known 
to induce powerful neutrophil-dominated pro-inflammatory 
responses (18, 23).
As illustrated in Figure  1A, no significant difference was 
observed on TNF-α obtained from BAL samples of mice treated 
with non-diluted PAO1 or with LPS; a dilution-dependent effect 
was observed from a dilution factor of 3 onward. These findings 
indicate that the non-diluted CM from PAO1 is as powerful as 
LPS to trigger pro-inflammatory responses. However, the cel-
lular component of the inflammatory response, characterized 
by a dominant neutrophil infiltrate, was significantly less in 
non-diluted PAO1 samples than in LPS samples (Figure  1B), 
suggesting a possible cytotoxic effect of CM. Compared to the 
non-diluted CM sample, a minor non-significant reduction of 
neutrophil count was observed with the dilution factor 3, while 
the cell count was reduced to about 50% or even to basal levels 
with higher dilution factors.
To better characterize the possible cytotoxic effect of CM, we 
monitored, in BAL fluid obtained 24 h after a single dose of serial 
CM dilutions, LDH activity as a marker of cytotoxicity, and total 
protein content as a maker of vascular permeability. LDH activity 
(Figure 1C) and total protein content (Figure 1D) were reduced 
with higher CM dilutions, suggesting a dilution-dependent cyto-
toxic effect of CM. However, as at the 3× dilution, near maximal 
cell counts were reached (Figure 1B) with an apparent reduction 
of cytotoxicity (Figure 1D), the 3× CM dilution was selected for 
the 24-h time point in further experiments.
To allow reducing the number of mice tested and tracking 
both early cytokine release responses and late cellular infiltrate 
FigUre 1 | Master cytokine [(a) TnF-α], neutrophil infiltrate (B), markers of cytotoxicity [(c) lactate dehydrogenase, (D) total protein] in the 
bronchoalveolar lavage of wild-type mice 3 h (a) or 24 h (B–D) after a single endotracheal instillation with serial dilutions (0, 3, 10, and 30 times) of 
cM collected from PaO1 cultures, in comparison with a standard lPs dose (50 μg/mouse) at the same time point or with saline. Data illustrate one of 
three representative independent experiments. Values are means ± SD for four animals per group. p-Values denote levels of significance of comparisons between 
PAO1 dilutions and LPS (supra) or non-diluted PAO1 samples (infra).
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responses in the same samples, a combined CM protocol was 
designed in which the second non-diluted CM solution was 
applied 3  h before sampling. In further experiments, the 
combined CM protocol consisted in the first dose diluted three 
times (shown to reduce possible cytotoxicity effects), followed 
by the second non-diluted dose (shown to induce maximal 
cytokine release responses). To validate the CM combined 
protocol, we compared values of master cytokines (IL-1β 
and TNF-α), cell counts, and markers of cytotoxicity in BAL 
samples obtained using either the CM combined protocol or 
the validated LPS combined protocol. The latter consisted in 
two subsequent LPS doses (50 and 100 μg) applied at a 21-h 
interval with sampling 3 h after the latter and larger dose (23). 
We confirmed here the efficacy of the LPS combined protocol 
to induce both early cytokine and late cellular responses 
(Figures 2A–C). We showed that the CM combined protocol 
was as effective as the LPS combined protocol to induce 
pro-inflammatory responses without significant differences 
in cytotoxicity. Indeed, similar values were obtained for total 
protein contents in BAL fluid (Figure  2D) and LDH activity 
(data not shown) in the two protocols. Altogether, these data 
indicate that, as the LPS model, CM has a strong neutrophil-
chemoattractant effect. Thus, the combined CM protocol is 
a valuable model to study both early (cytokine release) and 
late (cellular infiltrate) components of lung pro-inflammatory 
responses without apparent cytotoxic effects.
FigUre 3 | Quantification of lPs in cM obtained from PaO1 cultures, 
in comparison with lPs solutions. CM samples applied 24 or 3 h before 
sampling were diluted three times or not diluted. LPS dose applied 24 or 3 h 
before sampling was 50 or 100 μg. Data illustrate one of three representative 
independent experiments performed in triplicate. Values are means ± SD for 
three samples per group.
FigUre 2 | Master cytokines [(a) TnF-α; (B) il-1β], neutrophil infiltrate (c), and total protein content as a marker of cytotoxicity (D) in the 
bronchoalveolar lavage of wild-type mice after endotracheal instillation with the combined two-dose protocol of cM collected from PaO1 
cultures, in comparison with the combined two-dose lPs protocol or saline. Combined CM protocol consisted in a first dose diluted three times followed 
by a second non-diluted dose. Combined LPS protocol consisted in a first dose, 50 μg and a second dose, 100 μg. Interval between doses (50 μL) in both 
protocols was 21 h and sampling 3 h after the second dose. Data illustrate one of three representative independent experiments. Values are means ± SD for four 
animals per group, except for neutrophil count and total protein in the NaCl group (n = 3). p-Values denote levels of significance of comparisons between PAO1 
and LPS.
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Pro-inflammatory effects of cM are not 
Mainly related to lPs
To analyze whether the pro-inflammatory effects observed with 
CM collected from PAO1 were dependent on LPS released into 
the culture medium, the endotoxin was quantified in CM and 
in LPS solutions used for endotracheal instillation. Compared 
to LPS, the CM doses applied 24 and 3 h before sampling were 
about 300 times and 200 times lower (Figure 3). These findings 
indicate that the strong pro-inflammatory effects of CM from 
PAO1 are not mainly related to LPS but rather due to non-
LPS-related bacterial products released in the supernatant of 
cultures.
Pretreatment of Bacterial cultures with 
azithromycin reduces lung Pro-
inflammatory responses in cF Mice
To test the influence of azithromycin on the magnitude of lung 
inflammatory responses induced by CM collected from PAO1 
cultures treated or not treated with the macrolide, F508del-CF, 
and wild-type mice were instilled using the combined CM 
protocol.
Under control NaCl conditions, no significant differences were 
found in the lung inflammatory phenotype between F508del-CF 
and wild-type mice (Figures 4A–H). The mean (±SD) total cell 
count in BAL was 2.3 (±0.3) × 104 in the wild-type group and 2.4 
(±0.6) × 104 in the CF group. No genotype-associated differences 
were noted in the proportions of cell populations, i.e., neutrophils 
and macrophages (data not shown), in the expression of master 
cytokines (IL-1β and TNF-α IL-6), chemokines (MIP-2, KC, and 
MCP-1), IL-17 and the Th1-related cytokine, and IFN-γ, in BAL 
(Figures 4A–H).
After exposure to CM, the release of almost all cyto/
chemokines (except KC, MIP-2, and IL-6) was increased in 
F508del-CF compared to wild-type mice (Figures  4A–H). 
Interestingly, CM-induced IL-17 release was only triggered in the 
CF group and by CM PAO1 without azithromycin (Figure 4H). 
FigUre 4 | cytokines (a–h) in the bronchoalveolar lavage of wild-type and cF mice after endotracheal instillation with the combined two-dose 
protocol of cM collected from the PaO1 strain cultured in the absence (PaO1) or in the presence of azithromycin (PaO1 + aZM), in comparison with 
saline. Data illustrate one of three representative independent experiments. Values are means ± SD for seven animals in the wild-type group and three animals in 
the CF group. p-Values are indicated for comparisons between responses according to the genotype and to the presence of the macrolide.
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The observation is in line with clinical findings, suggesting that 
T helper 17 pathway may contribute to the CF lung pathology 
(30). In wild-type mice, no significant effect of azithromycin 
was detected on any of the cyto/chemokines analyzed. In CF 
mice, a significant effect of the macrolide was observed in all 
cyto/chemokines that were overexpressed in response to the 
CM exposure, in particular, MCP1, TNF-α, and IFN-γ. These 
data indicate that treating bacterial cultures with azithromycin 
FigUre 5 | influence of azithromycin on proteins released by Pseudomonas aeruginosa when cultured in the absence (PaO1) or in the presence of 
the macrolide (PaO1 + aZM). (a) Virtual 2D map (molecular weight, MW vs. isoelectric point, pI) of protein identified by means of MudPIT approach by analyzing 
CM from PAO1 (n = 3) and PAO1 + AZM (n = 3); red spots: proteins specifically identified in the CM of PAO1, yellow spots: proteins specifically identified in the CM 
of PAO1 + AZM, and blue spots: proteins identified in the CM of both PAO1 and PAO1 + AZM. (B) Venn diagram of proteins identified in the CM from PAO1 and 
PAO1 + AZM. (c) Hierarchical clustering of the CMs derived from PAO1 and PAO1 + AZM; heat map shows the spectral count of the proteins found differentially 
expressed when comparing PAO1 and PAO1 + AZM.
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attenuates the ability of the culture media to induce lung 
inflammatory responses. The attenuating effect of azithromycin 
on the inflammatory responses to CM exposure seems to be 
genotype-related: CF mice are more recipient than wild-type 
mice. We could postulate that the macrolide exerts its action 
in CF lung disease, at least partly, by inhibiting the NFκB 
pathway and/or the Th17 pathway.
Pretreatment of Bacterial cultures 
with azithromycin Promotes release 
of Bacterial Proteins Possibly reducing 
lung Pro-inflammatory responses in 
cF Mice
CM collected from PAO1 cultured in the presence or in the 
absence of azithromycin were next analyzed by means of MudPIT 
approach to identify candidate bacterial products as possible 
targets of the macrolide effect. Globally, following six MudPIT 
runs, 204 proteins were identified (Figure 5A, Data sheet S1 in 
Supplementary Material) and about 75% resulted with a total 
SpC > 2 (Table S1 in Supplementary Material). Of note, proteins 
released by CM cultured in the presence of azithromycin were 
twice as numerous as those released by the non-treated CM 
(Figure 5B). In this scenario, the semi-quantitative comparison 
between proteins released by P. aeruginosa in the presence or in 
the absence of the macrolide allowed identification of 57 dif-
ferentially expressed proteins the expression of which changed 
in a reproducible way in all samples analyzed (Figure 5C). In 
particular, five proteins (positive Dave value) were downregu-
lated in the CM collected from azithromycin-treated cultures, 
while 52 proteins were upregulated (negative Dave value) in CM 
from azithromycin-treated cultures (Table S2 in Supplementary 
Material). Most of the differentially expressed proteins were 
involved in transport and metabolic processes.
FigUre 6 | counts of colony-forming units (cFU) in conditioned 
medium obtained from PaO1 cultures grown in the presence or in the 
absence of azithromycin (aZM). Data are expressed as mean ± SD for six 
independent experiments performed in duplicate (**p < 0.01).
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Among proteins possibly attenuating virulence factors of 
P. aeruginosa pathogenesis, we found that treatment with azithro-
mycin downregulated the catalytic enzyme lysyl endopeptidase 
(prpL-PA4175) and the extracellular heme acquisition protein 
HasAp (hasAp-PA3704), an iron-regulated extracellular protein 
that captures free or hemoglobin-bound heme. The treatment 
upregulated S-adenosylmethionine synthase (metK-PA0546), 
involved in generation of the nucleoside 5′-methylthioadenosine 
(MTA) that has multiple anti-inflammatory properties (31, 32), 
and the chaperone protein DnaK (dnaK-PA4761), recognized as 
a modulator of macrophage phenotype able to drive polarization 
of macrophages to a M2 profile (33) involved in repair and resolu-
tion of inflammatory responses (34).
Many other proteins were found to be upregulated under 
the influence of azithromycin treatment. Some are cytotoxic 
exoproducts such as exoenzyme S (exoS-PA3841), exoenzyme 
T (exoT-PA0044), transporters, or metabolic (co)factors such 
as adenylate cyclase (ExoY-PA2191), elastase (lasB-PA3724), 
Fe(3+)-pyochelin receptor (fptA-PA4221), and transcriptional 
regulatory protein AlgP (algP-PA5253). In addition, dihydroli-
poyl dehydrogenases (lpdG-PA1587 and lpdV-PA2250), pro-
tecting the bacterial pathogen from the action of the terminal 
complement pathway, were found upregulated in the presence 
of the macrolide. Altogether, these findings show that pretreat-
ment of Pseudomonas cultures with azithromycin promotes a 
differential release in the culture medium of a combination of 
bacterial proteins possibly reducing lung pro-inflammatory 
responses in CF mice.
azithromycin has a Bactericidal effect 
on the PaO1 strain of Pseudomonas 
in culture
To get deeper insight into the mechanism of the reduction by 
azithromycin of the pro-inflammatory effect of Pseudomonas, 
we evaluated the effect of the macrolide on the number of 
colony-forming units (CFU) in the culture medium. We observed 
(Figure 6) that azithromycin reduced counts of CFU by over 60 
times, indicating a bactericidal effect on the PAO1 strain.
DiscUssiOn
The present work was designed to test the hypothesis that azithro-
mycin modulates lung inflammation by modifying the set of 
bacterial proteins released in the cultured medium. The growing 
interest in macrolide antibiotics as beneficial agents in CF followed 
the success of long-term erythromycin in the treatment of diffuse 
pan-bronchiolitis, a condition that exhibits striking similarities 
to CF (35, 36). Azithromycin, a macrolide structurally modified 
from erythromycin, is an “unconventional” antibacterial drug 
for which a growing body of evidence brought about by clinical 
experience (37) and clinical trials (12–16) has demonstrated 
beneficial in CF. Macrolide antibiotics inhibit bacterial growth 
by binding to the 23S rRNA in the 50S subunit of the bacterial 
ribosome, preventing the transfer of tRNA from the A to the P 
site of the ribosome (38, 39). How this mechanism translates into 
clinical efficacy is still a matter of debate. Numerous studies have 
addressed the issue focusing on both sides of the host/pathogen 
equation. Interestingly, it has been reported that azithromycin 
attenuates pro-inflammatory responses (18, 23) and promotes 
macrophage phagocytic activity properties (40) in the treat-
ment of infections involving azithromycin-resistant pathogens, 
such as the opportunistic P. aeruginosa (41). This suggests that 
anti-inflammatory and anti-virulence properties of azithromycin 
contribute to its beneficial effects. As this is a central issue in the 
management of CF, better understanding of its mechanism of 
action is highly relevant.
We showed here that CM collected from the reference bacte-
rial strain PAO1 represents a novel experimental model to study 
in vivo sterile inflammatory responses. CM from Pseudomonas 
cultures was shown to be as powerful a neutrophil-dominated 
pro-inflammatory model as LPS. Beyond its much lower LPS 
content, the large set of released bacterial proteins, demonstrated 
by proteomic analyses, has the additional advantage of triggering 
reactions that should be closer to those obtained with microbial 
models using live bacteria, but without bacterial infection. This 
is a major concern for managers of animal facilities housing 
immunodeprived or CF mouse colonies. Moreover, exposure 
to CM from PAO1 allows investigating inflammatory responses 
independently of clearance of bacteria, defective in CF. Indeed, it 
has been proposed that CFTR is a cellular receptor for binding, 
endocyting, and clearing P. aeruginosa from the normal lung 
(42–44). Even though it also allows studying responses that are 
independent of interactions of bacteria with epithelial cells, a 
drawback of the LPS model is that non-mucoid to mucoid conver-
sion of Pseudomonas, a poor prognosticator in CF, is associated 
with a loss of high molecular weight LPS species (45).
We confirmed here that the CF mouse model homozygous for 
the most common F508del-CFTR mutation displays exaggerated 
inflammatory responses (18, 23). We showed that responses 
to azithromycin seemed to be dependent on the CF genotype. 
Indeed, our data showed that in CF mutants, pretreatment of 
Pseudomonas cultures with azithromycin reduced the release of 
all cyto/chemokines that overresponded to exposure to CM.
The data we present here indicate that azithromycin releases 
a differential set of extracellular and intracellular bacterial 
10
Leal et al. Azithromycin Up/Downregulates Pseudomonas Proteins
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 499
proteins which may trigger anti-inflammatory reactions in the 
host. Using high-throughput screening procedures, the bacterial 
products were identified as taking part in a myriad of processes, 
such as regulation of immune responses, membrane transporter 
mechanisms, or as (co)factors, in metabolic processes. At least 
some of these products may play critical roles in attenuating the 
virulence of the bacteria. Among the few downregulated pro-
teins identified in CM collected from bacterial cultures treated 
with azithromycin, lysylendopeptidase, and heme acquisition 
protein, HasAp can be highlighted as targets of the anti-virulent 
effect of the macrolide. Lysylendopeptidase is a catalytic enzyme 
that specifically cleaves peptide bonds at the carboxyl side of 
lysine residues (46). It can be assumed that its downregulation 
exerts protective, anti-proteolytic effects on host tissues. Heme 
acquisition protein HasAp is a bacterial iron-regulated extracel-
lular heme-binding protein that is required for P. aeruginosa 
utilization of hemoglobin iron (47). It is known that the ability 
of P. aeruginosa to cause chronic infections in patients with CF 
also depends on iron-scavenging systems (48). Downregulation 
of heme acquisition protein HasAp is expected to negatively 
impact on bacterial virulence by reducing availability of hemo-
globin to the bacterium at the local host microenvironment level. 
Upregulation of DnaK and the S-adenosylmethionine synthase 
might also negatively impact on the virulence of the bacterium. 
The former is the major bacterial counterpart of the heat shock 
protein 70, found to act as an important immunomodulator of 
monocytes, dendritic cells (49–51), and macrophage responses. 
It has been recognized as being capable of polarizing mac-
rophages to the M2 phenotype by inducing higher arginase I 
activity, IL-10 production, and FIZZ1 and Ym1 expression (33). 
The latter generates S-adenosylmethionine which is converted 
into 5′-methylthioadenosine (MTA) (52), which has anti-
inflammatory properties (33). Based on the immunomodulating 
effect of DnaK, by driving M2 macrophage polarization, and on 
the anti-inflammatory effect of MTA on multiple cytokines, it 
can be assumed that treatment of Pseudomonas cultures with 
azithromycin induces a tolerogenic phenotype linked to the 
in  vivo anti-inflammatory effects we observed. The increased 
release of MTA, with anti-inflammatory properties, can be 
beneficial to the host responses.
It is more challenging to integrate data regarding expression 
of exoenzymes S and T and of other proteins, such as PopD 
and PopN, comprising the type III secretion system which is 
a key virulence strategy found in Gram-negative bacteria. 
They were found to be upregulated in azithromycin-treated 
bacterial cultures. In pathogenic bacteria, effector proteins 
composing the type III secretion system are secreted directly 
into the cytosol of host cells as a strategy to facilitate bacterial 
pathogenesis (53). ExoS and ExoT are bifunctional toxins with 
GTPase-activating protein and ADP-ribosyltransferase activi-
ties (54). PopD and PopN are hydrophobic proteins required for 
bacterial translocation of Exo S and T (55). Studies have shown 
that the type III secretion system specifically interferes with host 
cell signal transduction as well as other cellular processes to 
promote mucosal barrier injury, deregulation of innate immune 
responses, and prevention of wound repair (56). In particular, 
ExoS appears to elicit a cytotoxic phenotype in cultured 
cells, while ExoT interferes with host cell phagocytic activity. 
Accordingly, intratracheal administration of ExoS resulted in 
neutrophil infiltration and in intense inflammatory responses 
correlating with pulmonary damage in animal models (57) and 
in patients with CF (58).
Interestingly, a study focusing on corneal infection with P. 
aeruginosa in mice revealed that the exoenzymes S and T are 
essential mediators promoting induction of neutrophil apopto-
sis in vitro and in vivo (59). This feature could contribute, at least 
partly, to the reduced pro-inflammatory responses we observed 
with the macrolide. It is noteworthy that the presence of exotox-
ins and associated translocon proteins do not necessarily lead 
to cell toxicity. As a matter of fact, a pro-myelocytic cell line 
(HL-60) and a pro-monocytic cell line (U937) were found to 
be resistant to toxin injections even in the presence of PopB/D 
associated with host cell plasma membranes (60). Examination 
of host cell components, such as cholesterol, actin cytoskeleton 
network, and signal transduction pathways, indicated that they 
can modulate the injection of exotoxins into eukaryotic cyto-
plasm. The authors (60) concluded that the efficacy of exotoxins 
delivered into host cells depends on regulation of translocation 
processes and suggested possible cross-talks between eukaryotic 
cell and the pathogen at the level of exotoxin translocation. 
Further studies are clearly required to identify the precise 
mechanisms governing this network of interactions.
Our data provide evidence of an inhibitory effect on bacte-
rial growth has been documented, suggesting a bactericidal 
effect of the macrolide in the PAO1 strain. But in addition, 
we showed that the anti-inflammatory effect of azithromycin 
results from changes in a set of proteins released from differ-
ent bacterial compartments. The underlying molecular basis 
of the latter seems to act via a complex regulation of the host 
microenvironment. Modulation of metabolic processes could 
include cell differentiation of monocytes/dendritic cells and 
macrophages to an anti-inflammatory (M2) phenotype that is 
believed to promote cell protection, regeneration, and plasticity. 
Additionally, downregulation of catalytic reactions and iron 
availability can impact on limiting virulence of P. aeruginosa. 
Targeting products released by the bacterium can help to iden-
tify strategies preventing lung damage in patients with CF. The 
recent development of more easily manageable murine models 
of lung inflammation (61) might facilitate the screening of 
anti-inflammatory compounds using experimental conditions 
that might better mimic the clinical setting (individual bacteria 
strains isolated form patients, for example).
cOnclUsiOn
Supernatants collected from cultures of the reference bacterial 
strain PAO1 represent a novel experimental model to study 
in vivo sterile lung inflammatory responses in mice. Our com-
bined two-dose protocol is well suited to track at the same 
time point the early (cytokine) and the late (cell infiltrate) 
components of the inflammatory responses. Pretreatment 
of Pseudomonas cultures with azithromycin attenuates the 
inflammatory overresponses in CF mice. By proteomic analy-
ses, we showed that azithromycin releases a differential set of 
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extracellular and intracellular bacterial proteins which may 
trigger anti-inflammatory reactions in the host. Our work also 
provides evidence of an inhibitory effect on bacterial growth, 
suggesting a bactericidal effect of the macrolide in the PAO1 
strain.
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TaBle s1 | Proteins identified by analyzing supernatants of culture 
media collected from Pseudomonas aeruginosa cultured in the absence 
(PaO1; n = 3) or in the presence of pretreatment with azithromycin 
(PaO1 + aZM; n = 3). SpC, spectral count; aSPC, average spectral count; 
sSPC, spectral count sum; tot SpC, total spectral count.
TaBle s2 | Differentially expressed proteins by comparing the protein 
profiles of PaO1 and PaO1 + aZM cMs. SpC, spectral count; aSpC, average 
spectral count; emPAI, exponentially modified protein abundance index; LDA, 
linear discriminant analysis, Dave, differential average; DCI, differential confidence 
index. Positive Dave value (red) indicate upregulation in PAO 1 CM, while 
negative Dave value (blue) indicate upregulation in PAO1 + AZM CM. For each 
protein, MW, pI, biological processes, cellular component, and molecular 
function are shown.
DaTa sheeT s1 | Peptides identified by analyzing supernatants of 
culture media (cM) collected from Pseudomonas aeruginosa cultured in 
the absence (PaO1) or in the presence of pretreatment with azithromycin 
(PaO1 + aZM). The file contains six data sheets corresponding to the MudPIT 
replicates analysis (rep 1–3) of CMs. For each analysis, Protein accession, 
annotated sequence, confidence, PSM ambiguity, protein groups, missed 
cleavages, charge, rank, m/z [Da], MH + [Da], DeltaM [ppm], Delta m/z, and 
Xcorr are shown.
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